Nasdaq Issues Delisting Warning to NEXGEL Over Sub-$1.00 Share Price
NXGL sits 17% above its 52-week low of $0.56.
Summary
NEXGEL, INC. has received a deficiency letter from Nasdaq, indicating its failure to maintain the minimum $1.00 bid price for 30 consecutive business days. The company now has 180 calendar days, until October 19, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). This notice follows recent positive news on April 21 regarding a $5.5 million financing and the acquisition of Celularity's degenerative disease segment, suggesting these developments have not yet sufficiently boosted the stock price above the critical threshold. The delisting risk is a significant concern for the micro-cap company, especially given its prior 'going concern' warning in its latest 10-K, and could severely impact liquidity and investor confidence if not resolved. Investors will be watching for the company's plan to address the bid price deficiency.
At the time of this announcement, NXGL was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.56 to $2.97. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.